Literature DB >> 24976847

Metalloproteinases in hypertension and cardiac disease: differential expression and mutual regulation.

Ana-Maria Bosonea1, Xiang Wang1, Jeffrey Odenbach1, Carlos Fernandez-Patron2.   

Abstract

Arterial hypertension, a condition characterized by sustained elevated blood pressure, is associated with pathological cardiac remodeling (i.e. cardiac hypertrophy and fibrosis) and is a major risk factor for cardiac failure. These processes can be triggered by excess vasoconstrictive agonists, which induce metalloproteinase-dependent shedding of growth factors to transactivate growth factor receptors and initiate disease signaling. Here, we review emerging evidence that agonist-activated metalloproteinases exhibit different expression patterns and mutual transcriptional regulation during the development of hypertension and cardiac remodeling.

Entities:  

Year:  2011        PMID: 24976847      PMCID: PMC4071041          DOI: 10.1016/j.ddmod.2011.02.001

Source DB:  PubMed          Journal:  Drug Discov Today Dis Models        ISSN: 1740-6757


  56 in total

Review 1.  Molecular mechanisms of human hypertension.

Authors:  R P Lifton; A G Gharavi; D S Geller
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

Review 2.  Vascular smooth muscle growth: autocrine growth mechanisms.

Authors:  B C Berk
Journal:  Physiol Rev       Date:  2001-07       Impact factor: 37.312

3.  MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE.

Authors:  Jeffrey Odenbach; Xiang Wang; Stephan Cooper; Fung Lan Chow; Tatsujiro Oka; Gary Lopaschuk; Zamaneh Kassiri; Carlos Fernandez-Patron
Journal:  Hypertension       Date:  2010-11-15       Impact factor: 10.190

4.  Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy.

Authors:  Masanori Asakura; Masafumi Kitakaze; Seiji Takashima; Yulin Liao; Fuminobu Ishikura; Tsuyoshi Yoshinaka; Hiroshi Ohmoto; Koichi Node; Kohichiro Yoshino; Hiroshi Ishiguro; Hiroshi Asanuma; Shoji Sanada; Yasushi Matsumura; Hiroshi Takeda; Shintaro Beppu; Michihiko Tada; Masatsugu Hori; Shigeki Higashiyama
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

5.  Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries.

Authors:  Arundhathi Jeyabalan; Jacqueline Novak; Lee A Danielson; Laurie J Kerchner; Shannon L Opett; Kirk P Conrad
Journal:  Circ Res       Date:  2003-10-30       Impact factor: 17.367

6.  Individual matrix metalloproteinases control distinct transcriptional responses in airway epithelial cells infected with Pseudomonas aeruginosa.

Authors:  Sean Y Kassim; Sina A Gharib; Brigham H Mecham; Timothy P Birkland; William C Parks; John K McGuire
Journal:  Infect Immun       Date:  2007-10-08       Impact factor: 3.441

7.  Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy.

Authors:  Xiang Wang; Fung Lan Chow; Tatsujiro Oka; Li Hao; Ana Lopez-Campistrous; Sandra Kelly; Stephan Cooper; Jeffrey Odenbach; Barry A Finegan; Richard Schulz; Zamaneh Kassiri; Gary D Lopaschuk; Carlos Fernandez-Patron
Journal:  Circulation       Date:  2009-04-27       Impact factor: 29.690

8.  Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis.

Authors:  Xiang Wang; Tatsujiro Oka; Fung L Chow; Stephan B Cooper; Jeff Odenbach; Gary D Lopaschuk; Zamaneh Kassiri; Carlos Fernandez-Patron
Journal:  Hypertension       Date:  2009-07-06       Impact factor: 10.190

Review 9.  MMP-2: expression, activation and inhibition.

Authors:  M L Corcoran; R E Hewitt; D E Kleiner; W G Stetler-Stevenson
Journal:  Enzyme Protein       Date:  1996

Review 10.  Familial hematuria due to type IV collagen mutations: Alport syndrome and thin basement membrane nephropathy.

Authors:  Clifford E Kashtan
Journal:  Curr Opin Pediatr       Date:  2004-04       Impact factor: 2.856

View more
  2 in total

1.  Anti-proliferative effect of olmesartan on Tenon's capsule fibroblasts.

Authors:  Xuan Wang; Ya-Zhi Fan; Liang Yao; Jian-Ming Wang
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

2.  Targeting MMP-Regulation of Inflammation to Increase Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis.

Authors:  Eugenio Hardy; Carlos Fernandez-Patron
Journal:  Biomolecules       Date:  2021-03-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.